BOSTON--(BUSINESS WIRE)--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, today announced that it has been selected to provide neonatal screening technology to support an expanded screening program in the Netherlands. PerkinElmer will provide four tandem mass spectrometry-based systems, reagents and software to support the Netherlands’ five hospital screening centers. The partnership expands the country’s program – which is intended to reach each of the estimated 200,000 babies born annually in the Netherlands – from screening for three disorders to a total of 14 disorders.
